Already have an account? Sign in.
Excitement Builds for Skye Bioscience's Potential Weight Loss Game-Changer
Skye Bioscience's promising, safe weight loss drug, nimacimab, earned a "Buy" rating and $20 price target from analysts.
Skye Bioscience's promising, safe weight loss drug, nimacimab, earned a "Buy" rating and $20 price target from analysts.
Adobe reported strong Q2 results and raised its full-year guidance, but shares fell after the company announced that CFO Dan Durn will step down on June 15 to pursue a new opportunity.
TeraWulf, Cipher Digital, Hut 8, and Fluidstack secure major Anthropic leases backed by Google in a landmark $35 billion financing package.
Adial Pharmaceuticals acquires Azora Therapeutics and raises up to $64 million to advance AT177, a novel colon-targeted therapy for ulcerative colitis. Phase 1 studies planned for mid-2027.